Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Sarcoma, Kaposi 3Epstein-Barr Virus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Immune Reconstitution Inflammatory Syndrome 1Cytomegalovirus Infections 1Castleman Disease 1

Interventions

Cisplatin 4pembrolizumab 3Nivolumab 3Fluorouracil 2Carboplatin 2toripalimab 1spartalizumab 1fludarabine phosphate 1fludarabine 1cc-486 1camrelizumab 1Vorinostat 1Valganciclovir 1Range of Motion, Articular 1Radiotherapy 1Radiosurgery 1Protons 1Platinum 1Methylprednisolone 1Medicare Part B 1Laryngoscopes 1Gemcitabine 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1Azacitidine 1Adrenal Cortex Hormones 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Nasopharyngeal Carcinoma × Valganciclovir × Clear all
NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡